Pesquisa | BVS Odontologia

1.

Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer.

Herzog, Thomas J; Pignata, Sandro; Ghamande, Sharad A; Rubio, Maria-Jesús; Fujiwara, Keiichi; Vulsteke, Christof; Armstrong, Deborah K; Sehouli, Jalid; Coleman, Robert L; Gabra, Hani; Scambia, Giovanni; Monk, Bradley J; Arranz, José A; Ushijima, Kimio; Hanna, Rabbie; Zamagni, Claudio; Wenham, Robert M; González-Martín, Antionio; Slomovitz, Brian; Jia, Yan; Ramsay, Lisa; Tewari, Krishnansu S; Weil, Susan C; Vergote, Ignace B.

Gynecol Oncol ; 170: 300-308, 2023 03.

Artigo em Inglês | MEDLINE | ID: mdl-36758420

2.

Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial.

Pfisterer, Jacobus; Shannon, Catherine M; Baumann, Klaus; Rau, Joern; Harter, Philipp; Joly, Florence; Sehouli, Jalid; Canzler, Ulrich; Schmalfeldt, Barbara; Dean, Andrew P; Hein, Alexander; Zeimet, Alain G; Hanker, Lars C; Petit, Thierry; Marmé, Frederik; El-Balat, Ahmed; Glasspool, Rosalind; de Gregorio, Nikolaus; Mahner, Sven; Meniawy, Tarek M; Park-Simon, Tjoung-Won; Mouret-Reynier, Marie-Ange; Costan, Cristina; Meier, Werner; Reinthaller, Alexander; Goh, Jeffrey C; L'Haridon, Tifenn; Baron Hay, Sally; Kommoss, Stefan; du Bois, Andreas; Kurtz, Jean-Emmanuel.

Lancet Oncol ; 21(5): 699-709, 2020 05.

Artigo em Inglês | MEDLINE | ID: mdl-32305099

3.

Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer - a randomized phase III trial (AGO-OVAR 2.29/ENGOT-ov34).

Harter, Philipp; Pautier, Patricia; Van Nieuwenhuysen, Els; Reuss, Alexander; Redondo, Andres; Lindemann, Kristina; Kurzeder, Christian; Petru, Edgar; Heitz, Florian; Sehouli, Jalid; Degregorio, Nikolaus; Wimberger, Pauline; Burges, Alexander; Cron, Nadin; Ledermann, Jonathan; Lorusso, Domenica; Paoletti, Xavier; Marme, Frederik.

Int J Gynecol Cancer ; 30(12): 1997-2001, 2020 12.

Artigo em Inglês | MEDLINE | ID: mdl-32606097

4.

Phase II Study Evaluating PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecologic Sarcomas and Mixed Epithelial-Mesenchymal Tumors A Phase II Protocol of the Arbeitsgemeinschaft Gynaekologische Onkologie Study Group (AGO-GYN 7).

Harter, Philipp; Sehouli, Jalid; Reuss, Alexander; Baumann, Klaus; Hanker, Lars; Kimmig, Rainer; Schröder, Willibald; Burges, Alexander; Gropp-Meier, Martina; Kurzeder, Christian; Mahner, Sven; Canzler, Ulrich; Lück, Hans-Joachim; Meier, Werner; Fehm, Tanja; du Bois, Andreas.

Int J Gynecol Cancer ; 26(9): 1636-1641, 2016 11.

Artigo em Inglês | MEDLINE | ID: mdl-27654266

5.

Impact of secondary cytoreductive surgery on survival in patients with platinum sensitive recurrent ovarian cancer: analysis of the CALYPSO trial.

Lee, Chee Khoon; Lord, Sarah; Grunewald, Tami; Gebski, Val; Hardy-Bessard, Anne-Claire; Sehouli, Jalid; Woie, Kathrine; Heywood, Mark; Schauer, Christian; Vergote, Ignace; Scambia, Giovanni; Ferrero, Annamaria; Harter, Philipp; Pujade-Lauraine, Eric; Friedlander, Michael.

Gynecol Oncol ; 136(1): 18-24, 2015 Jan.

Artigo em Inglês | MEDLINE | ID: mdl-25281492

6.

Efficient prevention strategy against the development of a palmar-plantar erythrodysesthesia during chemotherapy.

Lademann, Juergen; Martschick, Anja; Kluschke, Franziska; Richter, Heike; Fluhr, Joachim W; Patzelt, Alexa; Jung, Sora; Chekerov, Radoslav; Darvin, Maxim E; Haas, Norbert; Sterry, Wolfram; Zastrow, Leonhard; Sehouli, Jalid.

Skin Pharmacol Physiol ; 27(2): 66-70, 2014.

Artigo em Inglês | MEDLINE | ID: mdl-23969763

7.

Addition of vandetanib to pegylated liposomal doxorubicin (PLD) in patients with recurrent ovarian cancer. A randomized phase I/II study of the AGO Study Group (AGO-OVAR 2.13).

Harter, Philipp; Sehouli, Jalid; Kimmig, Rainer; Rau, Jörn; Hilpert, Felix; Kurzeder, Christian; Elser, Gabriele; du Bois, Andreas.

Invest New Drugs ; 31(6): 1499-504, 2013 Dec.

Artigo em Inglês | MEDLINE | ID: mdl-24005613

8.

MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum.

Monk, Bradley J; Grisham, Rachel N; Banerjee, Susana; Kalbacher, Elsa; Mirza, Mansoor Raza; Romero, Ignacio; Vuylsteke, Peter; Coleman, Robert L; Hilpert, Felix; Oza, Amit M; Westermann, Anneke; Oehler, Martin K; Pignata, Sandro; Aghajanian, Carol; Colombo, Nicoletta; Drill, Esther; Cibula, David; Moore, Kathleen N; Christy-Bittel, Janna; Del Campo, Josep M; Berger, Regina; Marth, Christian; Sehouli, Jalid; O'Malley, David M; Churruca, Cristina; Boyd, Adam P; Kristensen, Gunnar; Clamp, Andrew; Ray-Coquard, Isabelle; Vergote, Ignace.

J Clin Oncol ; 38(32): 3753-3762, 2020 11 10.

Artigo em Inglês | MEDLINE | ID: mdl-32822286

9.

Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts.

von Moos, Roger; Thuerlimann, Beat J K; Aapro, Matti; Rayson, Daniel; Harrold, Karen; Sehouli, Jalid; Scotte, Florian; Lorusso, Domenica; Dummer, Reinhard; Lacouture, Mario E; Lademann, Jürgen; Hauschild, Axel.

Eur J Cancer ; 44(6): 781-90, 2008 Apr.

Artigo em Inglês | MEDLINE | ID: mdl-18331788

10.

Brain metastases in relapsed epithelial ovarian cancer after chemotherapy with pegylated liposomal doxorubicin.

Kasprowicz, Nikola Serena; Fotopoulou, Christina; Oskay-Ozcelik, Gülten; El, Khalfaoui Khalid; Boehmer, Dirk; Sehouli, Jalid.

Anticancer Res ; 28(3B): 1943-6, 2008.

Artigo em Inglês | MEDLINE | ID: mdl-18630485

11.

Biweekly pegylated liposomal doxorubicin as second-line treatment in patients with relapsed ovarian cancer after failure of platinum and paclitaxel: results from a multi-center phase II study of the NOGGO.

Oskay-Oezcelik, Guelten; Koensgen, Dominique; Hindenburg, Hans-Joachim; Klare, Peter; Schmalfeldt, Barbara; Lichtenegger, Werner; Chekerov, Radoslav; Al-Batran, Salah-Eddin; Neumann, Ulf; Sehouli, Jalid.

Anticancer Res ; 28(2B): 1329-34, 2008.

Artigo em Inglês | MEDLINE | ID: mdl-18505074

12.

Conclusion.

Sehouli, Jalid.

Future Oncol ; 9(12 Suppl): 41, 2013 Dec.

Artigo em Inglês | MEDLINE | ID: mdl-24195530

13.

Trabectedin plus pegylated liposomal doxorubicin (PLD) for patients with platinum-sensitive recurrent ovarian cancer: a prospective, observational, multicenter study.

Runnebaum, Ingo B; Reichert, Dietmar; Ringsdorf, Uta; Kuther, Markus; Hesse, Tobias; Sehouli, Jalid; Wimberger, Pauline.

J Cancer Res Clin Oncol ; 144(6): 1185-1195, 2018 Jun.

Artigo em Inglês | MEDLINE | ID: mdl-29623421

14.

Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse.

Pujade-Lauraine, Eric; Wagner, Uwe; Aavall-Lundqvist, Elisabeth; Gebski, Val; Heywood, Mark; Vasey, Paul A; Volgger, Birgit; Vergote, Ignace; Pignata, Sandro; Ferrero, Annamaria; Sehouli, Jalid; Lortholary, Alain; Kristensen, Gunnar; Jackisch, Christian; Joly, Florence; Brown, Chris; Le Fur, Nathalie; du Bois, Andreas.

J Clin Oncol ; 28(20): 3323-9, 2010 Jul 10.

Artigo em Inglês | MEDLINE | ID: mdl-20498395

15.

Pegylated liposomal doxorubicin (CAELYX) in patients with advanced ovarian cancer: results of a German multicenter observational study.

Sehouli, Jalid; Camara, O; Schmidt, M; Mahner, S; Seipelt, G; Otremba, B; Schmalfeldt, B; Tesch, H; Lorenz-Schlüter, C; Oskay-Ozcelik, G.

Cancer Chemother Pharmacol ; 64(3): 585-91, 2009 Aug.

Artigo em Inglês | MEDLINE | ID: mdl-19156414

16.

Reduced incidence of severe palmar-plantar erythrodysesthesia and mucositis in a prospective multicenter phase II trial with pegylated liposomal doxorubicin at 40 mg/m2 every 4 weeks in previously treated patients with metastatic breast cancer.

Al-Batran, Salah-Eddin; Meerpohl, Hans-Gerd; von Minckwitz, Gunter; Atmaca, Akin; Kleeberg, Ulrich; Harbeck, Nadia; Lerbs, Werner; Hecker, Detlef; Sehouli, Jalid; Knuth, Alexander; Jager, Elke.

Oncology ; 70(2): 141-6, 2006.

Artigo em Inglês | MEDLINE | ID: mdl-16645327

BVS Odontologia

Informação e Conhecimento para a Saúde

Configurar filtros

Sua seleção (0)

Formato de exportação:

Exportar: